• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Brennan Nora

    2/7/25 8:16:59 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRAW alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Brennan Nora

    (Last) (First) (Middle)
    12 PENNS TRAIL

    (Street)
    NEWTOWN PA 18940

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/05/2025
    3. Issuer Name and Ticker or Trading Symbol
    Traws Pharma, Inc. [ TRAW ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim CFO
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Nora Brennan 02/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TRAW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRAW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRAW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Traws Pharma Reports First Quarter 2025 Results and Business Highlights

      FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the "Animal Rule" Additional briefing document in support of a meeting to align on ratutrelvir for COVID - including Long COVID - to be submitted to regulatory authorities in Q2 2025 Cash runway to support planned operations into Q1 2026 NEWTOWN, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from

      5/15/25 7:00:00 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Traws Pharma Reports Full Year 2024 Results and Business Highlights

      Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the "Animal Rule" Cash Runway to support planned operations into Q1 2026 Investor Update call today, March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human h

      3/31/25 9:00:00 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $TRAW
    Leadership Updates

    Live Leadership Updates

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

      Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of Service NEWTOWN, Pa., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer, today announced the appointment of Luba Greenwood as Director. In addition, Director James J. Marino is stepping down after nearly ten years of dedicated service, including four years as Chairman, due to other professional co

      9/20/24 7:30:00 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRAW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tpav, Llc disposed of 605,531 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/8/25 8:32:34 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Cautreels Werner exercised 96,348 shares at a strike of $0.01, increasing direct ownership by 1,204% to 104,348 units (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      2/19/25 6:23:35 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Guerin Mark Patrick

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      2/10/25 4:30:20 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRAW
    Financials

    Live finance-specific insights

    See more
    • Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

      Merger with Trawsfynydd Therapeutics, Inc ("Trawsfynydd") and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyond Lead antiviral program, tivoxavir marboxil, for influenza, including avian flu, is dosing the first cohort in the Phase 1 dose extension study in AustraliaCOVID-19 program, ratutrelvir, completed the Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) study in Australia Oncology strategy includes investigator-sponsored trials (ISTs), planned to begin in H2 2024, adding a new

      8/15/24 7:00:00 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

      NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ("Traws" or "Traws Pharma"), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced that following the release of its second quarter financial results, the Company intends to host a conference call and live webcast on Thursday, August 15, at 8:00 AM ET to provide a corporate update. Conference Call and Webcast InformationDate: Thursday, August 15, 2024Time: 8:00 AM ETWebcast Link: Traws Pharma Corporate Update Call Dial-in Numbers: (877) 407-0789 (United States), (201) 689-8562 (International)Conference ID: 13748066 The press release with the f

      8/14/24 4:30:00 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

      Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024 for our influenza candidate and ritonavir-free COVID 19 protease inhibitor NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ("Traws" or "Traws Pharma"), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update. "2024 has already been a transformative year for Traws Pharma to advance our portfolio of

      5/16/24 9:29:19 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRAW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Traws Pharma Inc.

      SC 13D/A - Traws Pharma, Inc. (0001130598) (Subject)

      11/6/24 4:12:57 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Traws Pharma Inc.

      SC 13D - Traws Pharma, Inc. (0001130598) (Subject)

      9/23/24 6:44:56 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRAW
    SEC Filings

    See more
    • Traws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Traws Pharma, Inc. (0001130598) (Filer)

      5/19/25 8:00:47 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Traws Pharma Inc.

      SCHEDULE 13G/A - Traws Pharma, Inc. (0001130598) (Subject)

      5/15/25 5:26:46 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Traws Pharma Inc.

      10-Q - Traws Pharma, Inc. (0001130598) (Filer)

      5/15/25 4:01:33 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care